Wechselwirkungen · Truvada
Truvada 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-113726 · Präparat HOS-093961
Tenofovir: AUC: ↓ 2% (↓ 5 to ↑ 0) Cmax: ↓ 1% (↓ 7 to ↑ 6) Cmin: NC Hepatitis C virus (HCV) antiviral agents Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations (90 mg/400 mg q.d.) + AUC: ↑ 96% (↑ 74 to ↑ 121) of tenofovir resulting from Atazanavir/Ritonavir Cmax: ↑ 68% (↑ 54 to ↑ 84) co-administration of tenofovir (300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% (↑ 91 to ↑ 150) disoproxil, ledipasvir/sofosbuvir Emtricitabine/Tenofovir disoproxil and atazanavir/ritonavir may (200 mg/245 mg q.d.)1 Sofosbuvir: increase adverse reactions related AUC: ↔ to tenofovir disoproxil, including Cmax: ↔ renal disorders. The safety of tenofovir disoproxil when used GS-3310072: with ledipasvir/sofosbuvir and a AUC: ↔ pharmacokinetic enhancer (e.g. Cmax: ↔ ritonavir or cobicistat) has not Cmin: ↑ 42% (↑ 34 to ↑ 49) been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) hepatitis C virus (HOS-108813) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T18:10:00Z · SHA-256 c649f98085684f03838a5e69a1a4e7a871850d61dfdc001f745e6b31db212087 · Passage 036f429b643f0e27b6cbf765f88080762e068efbc27b6624fbf75c16b828aa67 · Zeichen 10432–11945 im Abschnitt